Developing TRAIL/TRAIL death receptor-based cancer therapies
Тип публикации: Journal Article
Дата публикации: 2018-03-14
scimago Q1
wos Q1
БС1
SJR: 2.596
CiteScore: 14.0
Impact factor: 8.7
ISSN: 01677659, 15737233
PubMed ID:
29541897
Cancer Research
Oncology
Краткое описание
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily that can initiate the apoptosis pathway by binding to its associated death receptors DR4 and DR5. The activation of the TRAIL pathway in inducing tumor-selective apoptosis leads to the development of TRAIL-based cancer therapies, which include recombinant forms of TRAIL, TRAIL receptor agonists, and other therapeutic agents. Importantly, TRAIL, DR4, and DR5 can all be induced by synthetic and natural agents that activate the TRAIL apoptosis pathway in cancer cells. Thus, understanding the regulation of the TRAIL apoptosis pathway can aid in the development of TRAIL-based therapies for the treatment of human cancer.
Найдено
Ничего не найдено, попробуйте изменить настройки фильтра.
Найдено
Ничего не найдено, попробуйте изменить настройки фильтра.
Топ-30
Журналы
|
2
4
6
8
10
|
|
|
Cancers
10 публикаций, 4.81%
|
|
|
Pharmaceutics
5 публикаций, 2.4%
|
|
|
Frontiers in Immunology
4 публикации, 1.92%
|
|
|
Frontiers in Molecular Biosciences
4 публикации, 1.92%
|
|
|
Frontiers in Oncology
4 публикации, 1.92%
|
|
|
Frontiers in Pharmacology
4 публикации, 1.92%
|
|
|
Molecules
3 публикации, 1.44%
|
|
|
International Journal of Molecular Sciences
3 публикации, 1.44%
|
|
|
Biomedicine and Pharmacotherapy
3 публикации, 1.44%
|
|
|
Journal of Zhejiang University: Science B
3 публикации, 1.44%
|
|
|
Oncology Reports
3 публикации, 1.44%
|
|
|
Oncology Letters
3 публикации, 1.44%
|
|
|
Cells
2 публикации, 0.96%
|
|
|
Biomolecules
2 публикации, 0.96%
|
|
|
Pharmaceuticals
2 публикации, 0.96%
|
|
|
Frontiers in Cell and Developmental Biology
2 публикации, 0.96%
|
|
|
Frontiers in Bioengineering and Biotechnology
2 публикации, 0.96%
|
|
|
Cancer Cell International
2 публикации, 0.96%
|
|
|
Signal Transduction and Targeted Therapy
2 публикации, 0.96%
|
|
|
Journal of Hematology and Oncology
2 публикации, 0.96%
|
|
|
Apoptosis : an international journal on programmed cell death
2 публикации, 0.96%
|
|
|
Cancer Letters
2 публикации, 0.96%
|
|
|
Acta Biomaterialia
2 публикации, 0.96%
|
|
|
International Journal of Pharmaceutics
2 публикации, 0.96%
|
|
|
European Journal of Medicinal Chemistry
2 публикации, 0.96%
|
|
|
Medical Oncology
2 публикации, 0.96%
|
|
|
ACS Nano
2 публикации, 0.96%
|
|
|
Bioengineered
2 публикации, 0.96%
|
|
|
Neuro-Oncology
2 публикации, 0.96%
|
|
|
2
4
6
8
10
|
Издатели
|
5
10
15
20
25
30
35
40
45
50
|
|
|
Elsevier
47 публикаций, 22.6%
|
|
|
Springer Nature
35 публикаций, 16.83%
|
|
|
MDPI
33 публикации, 15.87%
|
|
|
Frontiers Media S.A.
21 публикация, 10.1%
|
|
|
Taylor & Francis
12 публикаций, 5.77%
|
|
|
Wiley
12 публикаций, 5.77%
|
|
|
Spandidos Publications
6 публикаций, 2.88%
|
|
|
American Chemical Society (ACS)
4 публикации, 1.92%
|
|
|
Royal Society of Chemistry (RSC)
3 публикации, 1.44%
|
|
|
Oxford University Press
3 публикации, 1.44%
|
|
|
Zhejiang University Press
3 публикации, 1.44%
|
|
|
American Association for Cancer Research (AACR)
3 публикации, 1.44%
|
|
|
Cold Spring Harbor Laboratory
3 публикации, 1.44%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
2 публикации, 0.96%
|
|
|
Bentham Science Publishers Ltd.
1 публикация, 0.48%
|
|
|
Bioscientifica
1 публикация, 0.48%
|
|
|
IOS Press
1 публикация, 0.48%
|
|
|
S. Karger AG
1 публикация, 0.48%
|
|
|
Mary Ann Liebert
1 публикация, 0.48%
|
|
|
Portland Press
1 публикация, 0.48%
|
|
|
Baishideng Publishing Group
1 публикация, 0.48%
|
|
|
King Saud University
1 публикация, 0.48%
|
|
|
American Society for Biochemistry and Molecular Biology
1 публикация, 0.48%
|
|
|
Georg Thieme Verlag KG
1 публикация, 0.48%
|
|
|
BMJ
1 публикация, 0.48%
|
|
|
American Institute of Mathematical Sciences (AIMS)
1 публикация, 0.48%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
1 публикация, 0.48%
|
|
|
eLife Sciences Publications
1 публикация, 0.48%
|
|
|
IntechOpen
1 публикация, 0.48%
|
|
|
5
10
15
20
25
30
35
40
45
50
|
- Мы не учитываем публикации, у которых нет DOI.
- Статистика публикаций обновляется еженедельно.
Вы ученый?
Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
Метрики
209
Всего цитирований:
209
Цитирований c 2025:
35
(16.83%)
Цитировать
ГОСТ |
RIS |
BibTex |
MLA
Цитировать
ГОСТ
Скопировать
Yuan X. et al. Developing TRAIL/TRAIL death receptor-based cancer therapies // Cancer and Metastasis Reviews. 2018. Vol. 37. No. 4. pp. 733-748.
ГОСТ со всеми авторами (до 50)
Скопировать
Yuan X., Gajan A., Chu Q., XIONG H., Wu K., Wu G. S. Developing TRAIL/TRAIL death receptor-based cancer therapies // Cancer and Metastasis Reviews. 2018. Vol. 37. No. 4. pp. 733-748.
Цитировать
RIS
Скопировать
TY - JOUR
DO - 10.1007/s10555-018-9728-y
UR - https://doi.org/10.1007/s10555-018-9728-y
TI - Developing TRAIL/TRAIL death receptor-based cancer therapies
T2 - Cancer and Metastasis Reviews
AU - Yuan, Xun
AU - Gajan, Ambikai
AU - Chu, Qian
AU - XIONG, HUA
AU - Wu, Kongming
AU - Wu, Gen Sheng
PY - 2018
DA - 2018/03/14
PB - Springer Nature
SP - 733-748
IS - 4
VL - 37
PMID - 29541897
SN - 0167-7659
SN - 1573-7233
ER -
Цитировать
BibTex (до 50 авторов)
Скопировать
@article{2018_Yuan,
author = {Xun Yuan and Ambikai Gajan and Qian Chu and HUA XIONG and Kongming Wu and Gen Sheng Wu},
title = {Developing TRAIL/TRAIL death receptor-based cancer therapies},
journal = {Cancer and Metastasis Reviews},
year = {2018},
volume = {37},
publisher = {Springer Nature},
month = {mar},
url = {https://doi.org/10.1007/s10555-018-9728-y},
number = {4},
pages = {733--748},
doi = {10.1007/s10555-018-9728-y}
}
Цитировать
MLA
Скопировать
Yuan, Xun, et al. “Developing TRAIL/TRAIL death receptor-based cancer therapies.” Cancer and Metastasis Reviews, vol. 37, no. 4, Mar. 2018, pp. 733-748. https://doi.org/10.1007/s10555-018-9728-y.